Actinium Pharmaceuticals to Showcase Innovative Cancer Treatments at AACR Annual Meeting 2026
- Actinium Pharmaceuticals will present innovative cancer treatments ATNM-400 and Actimab-A at AACR Annual Meeting 2026.
- The presentations will emphasize the potential advancements of its Ac-225 platform in cancer therapy.
- Actinium is dedicated to improving treatment efficacy while reducing toxicity to healthy tissues.
Actinium Pharmaceuticals, Inc. is set to unveil new preclinical data for its promising radioconjugate ATNM-400 and its acute myeloid leukemia (AML) treatment, Actimab-A, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026. Scheduled from April 17-22, 2026, in San Diego, California, these presentations will showcase critical findings that highlight the first-in-class efficacy of ATNM-400 across various solid tumor models. CEO Sandesh Seth emphasizes the versatility and potential of the Ac-225 platform, particularly its effectiveness against tumors that are resistant to standard therapies.
Related Cashu News
CRISPR Therapeutics AG Achieves Financial Progress Amid Advancements in Gene-Editing Portfolio
CRISPR Therapeutics AG (Ticker: UNDEFINED) showcases a pivotal moment in its financial journey with the release of its results for the first quarter of 2026. Highlighting a revenue of $1.46 million, t…
MetaVia to Present Innovative Cardiometabolic Research at 2026 ADA Scientific Sessions
MetaVia is set to showcase its innovative research in cardiometabolic diseases at the upcoming American Diabetes Association (ADA) Scientific Sessions in 2026, following the acceptance of three late-b…
Ionis Pharmaceuticals Advances TRYNGOLZA for Hypertriglyceridemia and Diranersen for Alzheimer's Disease
Ionis Pharmaceuticals has made headlines in the biotechnology sector with the promising potential of its drug TRYNGOLZA, which is designed to treat severe hypertriglyceridemia. During a recent healthc…
ImmunityBio Partners with BCG Laboratory to Enhance Bladder Cancer Treatment Supply and Options
ImmunityBio has secured a critical partnership with Japan's BCG Laboratory to enhance the supply of Bacillus Calmette-Guérin (BCG) in the United States, addressing an urgent need in the treatment of b…